Exclusive Summary

• Strongly backed by a valid registration in South Korea (a PIC/S member), effectively overcoming strict bio-safety barriers for animal-derived extracts and ensuring fast-track regulatory approvals in newly targeted markets.
• Targeting a massive demand for hepatic repair therapies addressing over 296 million HBV and 1 billion NAFLD patients globally, the 50mg enteric-coated capsule bridges the outpatient gap by preventing peptide degradation by gastric acid.
• Completely free from multinational originator patent restrictions and facing practically zero direct formulation competitors overseas, leveraging China's ultra-mature supply chain to generate outstanding cost advantages and lucrative distributor profit margins.

Asset Materials

Contact Us for Full Materials